Evidence map›Paper›PMID 42737853›Full record

SynthesisInternational journal of molecular sciences2026

Circulating Amyloid and Misfolded Biomarkers in Early Myocardial Injury: A Systematic Review and Epistemic Meta-Analysis.

Florencio Alejandro Chable-Guerrero, Diana Romero-Zertuche, Cristina Revilla-Monsalve, Lizett Castrejón-Delgado, Nelly F Altamirano-Bustamante, Myriam Marlenne Altamirano-Bustamante

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Florencio Alejandro Chable-GuerreroUMAE Hospital de Cardiología del Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de Mexico 06720, C.P., Mexico.
Diana Romero-ZertucheUMAE Hospital de Cardiología del Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de Mexico 06720, C.P., Mexico.ORCID 0000-0001-8622-9110
Cristina Revilla-MonsalveUnidad de Investigación en Enfermedades Metabólicas, UMAE Hospital de Cardiología del Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de Mexico 06720, C.P., Mexico.ORCID 0000-0002-6202-1160
Lizett Castrejón-DelgadoFacultad de Estudios Superiores Zaragoza (FES Zaragoza), Universidad Nacional Autónoma de Mexico (UNAM), Ciudad de Mexico 09230, C.P., Mexico.ORCID 0000-0001-5504-2353
Nelly F Altamirano-BustamanteServicio de Endocrinología, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, C.P., Mexico.ORCID 0000-0002-4361-9677
Myriam Marlenne Altamirano-BustamanteUnidad de Investigación en Enfermedades Metabólicas, UMAE Hospital de Cardiología del Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de Mexico 06720, C.P., Mexico.ORCID 0000-0001-7297-4689

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Misfolded proteins, including islet amyloid polypeptide (hIAPP), serum amyloid A (SAA), and amyloid-betas (Aβs) such as Aβ1-40 and Aβ1-42 oligomers, collectively referred to in our work as amyloid oligomers, have been implicated in the development of both metabolic and cardiovascular diseases. However, their potential role as early biomarkers of myocardial damage remains insufficiently explored. We conducted a systematic review following PRISMA guidelines and epistemic meta-analysis to investigate the association between misfolded protein oligomers and early myocardial injury. All English- and Spanish-language articles with titles, abstracts, or keywords relevant to the research topic and indexed in at least one of the following databases-PubMed, BIREME, or Web of Science-were included. A comprehensive search across major databases identified 30 eligible studies. Thirty studies met inclusion criteria, in humans and animals, and in vitro. Amyloid oligomers were consistently elevated in patients with acute myocardial infarction, type 2 diabetes, or coronary artery disease compared with controls. In specific individual cohorts, a higher SAA concentration correlated with major adverse cardiovascular events, where it acted as an independent predictor of mortality in reperfused AMI (RR 5.8; 95% CI: 1.3-27.7) and cardiac rupture (OR 8.8; 95% CI: 1.7-25.6). Our findings support the hypothesis that protein misfolding contributes to early myocardial injury and highlight its potential as a novel source of cardiometabolic biomarkers.

Indexed as

BiomarkersMyocardial InfarctionSerum Amyloid A ProteinAmyloid beta-PeptidesAnimalsHumansMyocardiumProtein FoldingAmyloid beta-PeptidesBiomarkersSerum Amyloid A Proteinamyloiddeathheart failurehIAPPmyocardial infarctionserum amyloid type A

Identifiers

PMID42737853
PMCPMC13566443

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.